This is an educational resource for health care professionals to learn more about the ongoing trial and to determine the eligibility for patient enrollment in the trial.
The PACIFICA trial is a randomized, controlled phase 3 study of pacritinib versus Physician's Choice1 in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or post‑essential thrombocythemia myelofibrosis with severe thrombocytopenia (platelet count <50,000/µL).
1Physician’s Choice is limited to single drugs from the following list: corticosteroids, hydroxyurea, danazol, or low-dose ruxolitinib.
Study is being conducted in following countries. For a full list of PACIFICA clinical sites and site enrollment status, visit ClinicalTrials.gov.
*Pacritinib (commercially known as VONJO™) was approved by U.S. Food and Drug Administration (FDA) on February 28, 2022 for the treatment of adults with myelofibrosis with a platelet count below 50 x 109/L.
As the approved indication is identical to the patients enrolling on PACIFICA, enrollment of additional patients in the U.S. is closed effective March 2022.